May 13, 2019
Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, said on May 10 that its investigational schizophrenia treatment SEP-363856 has been granted US FDA Breakthrough Therapy Designation. The compound is jointly developed with US-based PsychoGenics. It does not bind to...read more